Application Areas
Our VHH nanobodies and RNA solutions support research programs across four priority medical domains.
Immunotherapy
Thanks to their small size (~15 kDa) and high affinity, VHH nanobodies reach epitopes often inaccessible to conventional antibodies — active-site pockets, surface grooves, crowded regions. This makes them valuable tools for developing immunomodulatory agents targeting immune checkpoint receptors or cytokines.
Allergology
VHH nanobodies allow fine mapping of the epitopes recognized by IgE responsible for allergic reactions, and screening of candidates able to block allergen-IgE binding or neutralize receptors involved in the allergic cascade. Their stability also facilitates formulation for topical or inhaled applications.
Autoimmune Diseases
In chronic inflammatory conditions, VHH nanobodies offer targeted modulation of dysregulated immune pathways, with tissue penetration superior to conventional antibodies. They are being explored as alternatives or complements to existing biotherapies in rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Oncology
In oncology, VHH nanobodies are developed as bispecific formats (redirecting immune cells to the tumor), conjugated to cytotoxic payloads or radioisotopes (nanobody-drug conjugates), or used as molecular imaging tools for early diagnosis and treatment monitoring.
The properties that make nanobodies unique.
Small size
~15 kDa, about ten times smaller than a conventional antibody (~150 kDa), enabling better tissue penetration.
Stability
Increased resistance to temperature and denaturing conditions, easing formulation and storage.
Ease of production
Single domain, no chain assembly required, expressible in simple prokaryotic or eukaryotic systems.
Access to hidden epitopes
Convex paratope shape, able to bind grooves or pockets inaccessible to conventional antibodies.